Shiyu Chen

Shiyu Chen

Auto-generated profile, based on publicly available information

Shiyu Chen

Department of Gastrointestinal Surgery, South China Hospital, Medical School, Shenzhen University, Shenzhen, P. R. China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 October 2023 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
CWChanghao Wu
Changhao Wu
CZChenglong Zheng
Chenglong Zheng
SCShiyu Chen
Shiyu Chen
ZHZhiwei He
Zhiwei He
HHHao Hua
Hao Hua
CYChao Yu
Chao Yu
Pancreatic cancer (PC), a gastrointestinal tract malignant tumor, has a poor prognosis due to early metastasis and limited response to chemotherapy. Therefore, identifying novel therapeutic approaches for PC is critical. Epithelial–mesenchymal transition (EMT) is known as the vital progress in PC development, we constructed the EMT-related prognosis model to screen out that FOXQ1 probably involving in the EMT regulation. FOXQ1 has been linked to the malignant process in a number of cancers. However, its function in PC is unknown. In our work, the expression of FOXQ1 was elevated in PC tissues, and a high level of FOXQ1 in PC was linked to patients’ poor prognosis. FOXQ1 overexpression promoted aerobic glycolysis and enhanced PC cell proliferation, tumor stemness, invasion, and metastasis. Whereas, FOXQ1 silencing showed the reverse effect. Furthermore, mechanistic studies indicated that FOXQ1 promotes LDHA transcription, and thus modulates aerobic glycolysis to enhance PC cell proliferation, tumor stemness, invasion, and metastasis by increasing LDHA expression. Therefore, these novel data suggest that FOXQ1 may be a possible therapeutic target in PC.

9 November 2022 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
SCShiyu Chen
Shiyu Chen
KCKun Cai
Kun Cai
DZDijie Zheng
Dijie Zheng
YLYanqing Liu
Yanqing Liu
LLLin Li
Lin Li
CYChao Yu
Chao Yu
Pancreatic cancer (PC) is one of the most malignant types of cancer, and is characterized by early metastasis, limited response to chemotherapeutics, and poor prognosis. Therefore, there is an urgent need to explore new therapeutic strategies for PC treatment. Human rhomboid-like 2 (RHBDL2) is differentially expressed in cervical and breast cancer. However, the correlation between RHBDL2 and PC remains unclear. We found that RHBDL2 is highly expressed in human PC cells and tissues and is significantly associated with distant metastasis and poor survival of patients with PC. Gain- and loss-of-function assays indicated that RHBDL2 could accelerate PC cell proliferation and mobility in vitro and in vivo. The RNA-Seq results suggest that RHBDL2 may be involved in the activation of Notch signaling pathway. IMR-1 could restore the proliferation and metastatic capacity of PC cells mediated by RHBDL2. RHBDL2 interacted with and cleaved Notch1, resulting in the release of N1ICD. RHBDL2 decreased the ubiquitination level of N1ICD and collaborated with Ovarian tumor domain-containing 7B (OTUD7B) to stabilize N1ICD via the ubiquitin-proteasome pathway. RHBDL2 facilitated PC cell proliferation and mobility by stabilizing the N1ICD via the OTUD7B and activating the Notch signaling pathway. Thus, targeting this novel pathway may be a potential therapeutic strategy for PC.

26 December 2024 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
SCShiyu Chen
Shiyu Chen
ZHZhiwei He
Zhiwei He
KCKun Cai
Kun Cai
YZYan Zhang
Yan Zhang
HZHongyan Zhu
Hongyan Zhu
XXXundi Xu
Xundi Xu
Pancreatic cancer (PC) is one of the most lethal malignant tumors that lacks effective treatment, and gemcitabine-based chemoresistance occurs frequently. Therefore, new therapeutic strategies for PC are urgently needed. Tripartite motif containing 59 (TRIM59) plays an important role in breast and lung cancer chemoresistance. However, the association between TRIM59 and gemcitabine resistance in PC remains unclear. We identified TRIM59 as an innovative E3 ubiquitin ligase that activated Notch signaling in PC. TRIM59 levels were increased in PC and positively correlated with poor prognosis and gemcitabine resistance in PC patients. TRIM59 facilitated gemcitabine resistance in PC cells in vitro and in vivo. TRIM59 interacted with recombination signal binding protein for immunoglobulin kappa J region (RBPJ) and stabilized it by promoting K63-linked ubiquitination. RBPJ transcriptionally upregulated TRIM59 expression, forming a positive feedback loop with TRIM59. We identified a novel TRIM59 inhibitor, catechin, and confirmed that it sensitized PC cells to gemcitabine. TRIM59 conferred gemcitabine resistance in PC by promoting RBPJ K63-linked ubiquitination, followed by activating Notch signaling. Therefore, our study provides a promising target for gemcitabine sensitization in PC treatment.

7 August 2026 in Oncogene
Verified
Journal Article
Closed access
PDF file
WSWenting Song
Wenting Song
JLJianong Luo
Jianong Luo
KCKun Cai
Kun Cai
SCShiyu Chen
Shiyu Chen
SRSuye Ran
Suye Ran
CSChengyi Sun
Chengyi Sun

3 August 2026 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
KCKun Cai
Kun Cai
SCShiyu Chen
Shiyu Chen
GMGuoqing Ma
Guoqing Ma
WWWenhao Wu
Wenhao Wu
SWSongsheng Wang
Songsheng Wang
TWTianbao Wang
Tianbao Wang
Chemotherapy resistance is one of the important reasons for the low 5-year survival rate of patients with pancreatic cancer. Elucidating the mechanism of chemotherapy resistance is an important breakthrough direction for improving the prognosis. Here, PSMD14, a deubiquitinating enzyme frequently overexpressed in human pancreatic cancer, was demonstrated to mediate chemoresistance principally by activating the WNT/β-catenin pathway. Mechanistically, PSMD14 activated the WNT/β-catenin pathway by removing the K63-linked ubiquitination of DVL1 and promoting its translocation from the cytoplasm to the membrane, consequently facilitating the aerobic glycolysis and contributing to the chemoresistance of pancreatic cancer cells. Furthermore, activation of the WNT/β-catenin pathway promoted the transcription of PSMD14, and the PSMD14 inhibitor capzimin improved the sensitivity of pancreatic cancer cells to gemcitabine in cells, organoids, and mouse models. In conclusion, PSMD14 plays a critical role in regulating the activity of WNT/β-catenin and the sensitivity of pancreatic cancer to gemcitabine, suggesting that PSMD14 appears to be a promising therapeutic target for pancreatic cancer.

12 July 2023 in Research Square
Verified
Preprint
Open access
PDF file
CWChanghao Wu
Changhao Wu
CZChenglong Zheng
Chenglong Zheng
SCShiyu Chen
Shiyu Chen
ZHZhiwei He
Zhiwei He
HHHao Hua
Hao Hua
CYChao Yu
Chao Yu
Pancreatic cancer (PC), a gastrointestinal tract malignant tumor, has a poor prognosis due to early metastases and limited response to chemotherapy. Therefore, identifying novel therapeutic approaches for PC is critical. Epithelial-mesenchymal transition (EMT) was known as the vital progress in the PC development, we constructed the EMT-related prognosis model to screen out that FOXQ1 probably involving in the EMT regulation. FOXQ1 has been linked to the malignant process in a number of cancers. However, its function in PC is unknown. In our work, the expression of FOXQ1 was elevated in PC tissues, and high level of FOXQ1 in PC was linked to patients' poor prognosis. FOXQ1 overexpression promoted aerobic glycolysis and enhanced PC cell proliferation, tumor stemness, invasion and metastasis. Whereas, FOXQ1 silencing showed the reverse effect. Furthermore, mechanistic studies indicated that FOXQ1 promotes LDHA transcription, thus modulates aerobic glycolysis to enhance PC cell proliferation, tumor stemness, invasion, and metastasis by increasing LDHA expression. Therefore, these novel data suggest that FOXQ1 may be a possible therapeutic target in PC.